Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Ing Soo TiongDevendra K HiwaseEmad AbroAshish BajelEmma PalfreymanAshanka BeligaswatteJohn ReynoldsNatasha S AnsteeTamia NguyenSun LooChong Chyn ChuaMichael AshbyKaitlyn M WiltshireShaun FlemingChun Yew FongTse-Chieh TehPiers BlomberyRichard DilonAdam IveyAndrew H WeiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
For AML in first remission and either MRD or oligoblastic relapse, venetoclax plus LDAC is well tolerated and highly effective.
Keyphrases
- acute myeloid leukemia
- phase ii study
- low dose
- chronic lymphocytic leukemia
- high dose
- open label
- free survival
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- cancer therapy
- disease activity
- placebo controlled
- clinical trial
- squamous cell carcinoma
- single molecule
- ulcerative colitis
- radiation therapy
- drug delivery
- systemic lupus erythematosus
- rheumatoid arthritis